Equities research analysts expect Jounce Therapeutics, Inc. (NASDAQ:JNCE) to report earnings per share of ($0.25) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Jounce Therapeutics’ earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.45). The business is scheduled to issue its next earnings report on Wednesday, November 8th.

On average, analysts expect that Jounce Therapeutics will report full-year earnings of ($0.73) per share for the current financial year, with EPS estimates ranging from ($1.05) to ($0.50). For the next year, analysts anticipate that the business will report earnings of ($1.43) per share, with EPS estimates ranging from ($1.47) to ($1.37). Zacks’ EPS calculations are an average based on a survey of analysts that cover Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last issued its earnings results on Wednesday, August 9th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.04. The firm had revenue of $20.29 million for the quarter, compared to analyst estimates of $19.94 million. During the same period in the previous year, the company earned ($7.23) earnings per share.

Several equities research analysts recently weighed in on the company. Zacks Investment Research lowered Jounce Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Cowen and Company restated a “buy” rating on shares of Jounce Therapeutics in a research report on Friday, June 9th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $23.67.

COPYRIGHT VIOLATION WARNING: This piece was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this piece can be accessed at https://www.thecerbatgem.com/2017/09/07/brokerages-expect-jounce-therapeutics-inc-jnce-to-post-0-25-eps.html.

Jounce Therapeutics (NASDAQ:JNCE) opened at 15.43 on Thursday. The stock’s 50 day moving average price is $13.75 and its 200-day moving average price is $19.10. The firm has a market capitalization of $496.14 million and a price-to-earnings ratio of 571.48. Jounce Therapeutics has a 12 month low of $11.05 and a 12 month high of $29.29.

A number of large investors have recently made changes to their positions in JNCE. FMR LLC purchased a new position in Jounce Therapeutics during the first quarter valued at $82,387,000. Wellington Management Group LLP purchased a new position in Jounce Therapeutics during the first quarter valued at $34,814,000. Redmile Group LLC purchased a new position in Jounce Therapeutics during the first quarter valued at $22,523,000. Pharmstandard International S.A. purchased a new position in Jounce Therapeutics during the first quarter valued at $14,559,000. Finally, Omega Fund Management LLC purchased a new position in Jounce Therapeutics during the first quarter valued at $12,747,000. Institutional investors and hedge funds own 43.50% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Stock Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related stocks with our FREE daily email newsletter.